Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JN 301

Next Previous
Drug Profile

JN 301

Alternative Names: JN-301; KB-301

Latest Information Update: 10 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Krystal Biotech
  • Developer Jeune; Krystal Biotech
  • Class Gene therapies; Skin disorder therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Skin aging

Most Recent Events

  • 19 Feb 2026 JN 301 has patent protection in US, Japan, Australia, New Zealand and South Africa
  • 06 May 2025 Jeune Aesthetics plans a phase II trial in Skin wrinkles in fourth quarter of 2025
  • 28 Aug 2024 Interim efficacy and adverse events data from the phase I PEARL-1 trial in Skin aging released by Krystal Biotech

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top